Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 6,732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CHANGE Study Clear all
Completed Not applicable Interventional

A Non-significant Risk Clinical Study to Assess Perfusion Changes With Application of a TUS for Patients With PAD

NCT05100745
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Therapeutic Device
Device
Lead sponsor
Vibrato Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 23, 2026, 11:12 AM EDT
Completed No phase listed Observational

Biokinetics Study for Tc-99m MAG3 in Pediatric Molecular Imaging

NCT03107286
View directory record Official record
Conditions
Renal Disease
Interventions
Tc-99M-MAG3, Modification in acquisition protocol
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Months to 6 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 23, 2026, 11:12 AM EDT
Recruiting Not applicable Interventional

Nasal Dilator Therapy for Patulous Eustachian Tube Dysfunction

NCT07796139
View directory record Official record
Conditions
Patulous Eustachian Tube Dysfunction, Eustachian Tube Dysfunction
Interventions
Internal nasal dilator
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 11:12 AM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 23, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

NCT00609622
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
sunitinib, mFOLFOX6, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
81
States / cities
Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 23, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

NCT01221753
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Interventions
docetaxel, cisplatin, 5-FU, IMRT, cetuximab, carboplatin
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 23, 2026, 11:12 AM EDT
Recruiting No phase listed Observational

fMRI Accelerated TMS Depression

NCT06562153
View directory record Official record
Conditions
Depression
Interventions
Neuroimaging with Magnetic Resonance Imaging (MRI)
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

NCT00671970
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Erlotinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VL-3 Training Study

NCT05356754
View directory record Official record
Conditions
Hypertension, Blood Pressure
Interventions
The Vital Labs Digital Blood Pressure Monitor
Device
Lead sponsor
Riva Health
Industry
Eligibility
18 Years to 85 Years
Enrollment
343 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Francisco, California • Walnut Creek, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Not applicable Interventional

FODMAP Reintroduction in Irritable Bowel Syndrome

NCT03245645
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Mixed Bowel Habits
Interventions
Dietary Intervention
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 23, 2026, 11:12 AM EDT
Withdrawn Phase 2 Interventional

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

NCT04439305
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma
Interventions
Dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

NCT04226131
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Controls
Interventions
Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment
Other
Lead sponsor
Duke University
Other
Eligibility
25 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 23, 2026, 11:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

NCT05559853
View directory record Official record
Conditions
Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
Interventions
CEST-MRF
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction

NCT00005077
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Results available

Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity

NCT04441996
View directory record Official record
Conditions
COVID-19
Interventions
Therapeutic plasma exchange (TPE), Standard of care
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

NCT02033551
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Interventions
Veliparib, Carboplatin, Paclitaxel, FOLFIRI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 23, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT06649812
View directory record Official record
Conditions
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, Venetoclax
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
114
States / cities
Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Results available

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

NCT04538040
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
Drug
Lead sponsor
Quest Clinical Research
Other
Eligibility
45 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 23, 2026, 11:12 AM EDT
Terminated Phase 1 Interventional

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

NCT05169489
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
bbT369
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Stanford, California • Denver, Colorado • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 23, 2026, 11:12 AM EDT
Active, not recruiting Phase 1 Interventional

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT00586391
View directory record Official record
Conditions
B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19CAR-28-zeta T cells, Ipilimumab
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

NCT01736462
View directory record Official record
Conditions
Corneal Endothelial Cell Changes
Interventions
Mapracorat
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 23, 2026, 11:12 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
Drug · Diagnostic Test · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 11:12 AM EDT